Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...

What if the solution to Alzheimer’s disease lies not in combating the proteins that cause it, but in simply getting more ...

The Alzheimer’s epidemic continues to cast a shadow over the lives of millions. This disease erodes memories and cognitive ...

As the year comes to a close, experts from the Alzheimer's Association reflect on some of the hopeful advances in diagnosis, ...

A study from Washington University in St. Louis found taking suvorexant, a common insomnia medication, for two nights ...

Researchers from Washington University in St. Louis found people who took suvorexant, a common treatment for insomnia, for ...

CoV-2, the virus that causes Covid-19 disease, first emerged in China’s Wuhan, the evidence so far makes a convincing case ...

Anavex Life Sciences remains one of the few non-amyloid Alzheimer's drug developers. Find out why I rate AVXL stock as a Hold ...

Scientists from Boston University and other institutions have identified a blood biomarker that could help detect the ...

In a year plagued by the challenges of Alzheimer's disease, 2024 brought a glimmer of hope with the approval of the third new ...

This review provides an overview of Alzheimer’s disease (AD), discussing its complex pathophysiology, risk factors, and ...

Biogen has taken up an option on a technology developed by Denali that it thinks could help improve the safety and efficacy of amyloid-targeting drugs for Alzheimer’s disease. The technology ...